Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension

JAMA

2023-09-10

(Press-News.org) About The Study: Among individuals with uncontrolled hypertension in this randomized clinical trial that included 200 participants, use of lorundrostat was effective at lowering blood pressure compared with placebo, which will require further confirmatory studies.

Authors: Steven E. Nissen, M.D., of the Cleveland Clinic Foundation, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2023.16029)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Media advisory: This study is being released to coincide with presentation at the AHA Hypertension Scientific Sessions 2023.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.16029?guestAccessKey=8562c91f-ed8a-4d65-a734-fc1a3433285a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091023

END

ELSE PRESS RELEASES FROM THIS DATE:

Benmelstobart plus anlotinib and chemotherapy shows benefit for patients with extensive-stage small-cell lung cancer

2023-09-10

[Singapore -- 10:35 a.m. SGT--September 10, 2023] - The combination of benmelstobart, anlotinib, and chemotherapy demonstrated significant benefits compared to placebo and chemotherapy in terms of median progression-free survival and overall survival for patients with extensive-stage small-cell lung cancer. The research was presented today at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore. Extensive-stage small-cell lung cancer is a challenging malignancy to treat, ...

Exhaled breath analysis shows promise in detecting malignant pleural mesothelioma

2023-09-10

[Singapore -- 10:35 a.m. SGT--September 10, 2023] -- Identifying and analyzing volatile organic compounds in exhaled breath of patients with malignant pleural mesothelioma showed promise as a screening method for MPM, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore. Malignant pleural mesothelioma (MPM) is a challenging disease with limited treatment options and a poor prognosis. To improve ...

Six-year follow-up data on CheckMate 227 survival and quality of life benefits unveiled for patients with metastatic NSCLC and nivolumab + ipilimumab treatment

2023-09-10

[Singapore -- 10:35 a.m. SGT--September 10, 2023) -- The International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore is set to witness a monumental breakthrough in the field of metastatic non-small cell lung cancer (NSCLC) treatment. Research findings from the CheckMate 227 trial will be presented, shedding light on the extraordinary six-year survival and quality of life benefits associated with first-line nivolumab + ipilimumab therapy. CheckMate 227 Part 1 showed that a combination ...

KRYSTAL-1 trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations

2023-09-10

[Singapore -- 10:35 a.m. SGT--September 10, 2023] — The oral, selective KRAS G12C inhibitor The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore. KRAS-G12C mutations occur in approximately 14% of patients with NSCLC. The KRYSTAL-1 study, a multi-cohort Phase 1/2 trial, evaluated adagrasib as a monotherapy or in combination for patients with KRAS-G12C-mutated ...

Stigmatization of smoking-related diseases is a barrier to care and the problem may be on the rise

2023-09-10

[Singapore -- 10:35 a.m. SGT--September 10, 2023) –The stigma that patients face when diagnosed with lung cancer is associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore. The study, conducted by a team of researchers led by Nathan Harrison, a behavioral scientist and PhD student ...

Color of phlegm can predict outcomes for patients with the lung disease, bronchiectasis

2023-09-10

Milan, Italy: The colour of the phlegm from patients with the lung disease bronchiectasis can indicate the degree of inflammation in their lungs and predict their future outcomes, according to new research presented at the European Respiratory Society International Congress in Milan, Italy [1]. The study of nearly 20,000 patients from 31 countries is the first time that the colour of phlegm (also known as sputum) has been shown to provide clinically relevant information that reflects prognoses and, therefore, can aid decisions about ...

Scientists set sights on protein that controls skeletal muscle composition

2023-09-09

Tokyo, Japan – Researchers from Tokyo Metropolitan University have shown that the protein Musashi-2 (Msi2) plays a key role in the regulation of mass and metabolic processes in skeletal muscle. They studied mice with the Msi2 gene knocked out and found reduced muscle mass due to fewer type 2a muscle fibers. Myoglobin and mitochondria were also reduced. Type 2a fibers respond sensitively to training and illnesses; insights into their regulation will prove valuable in new therapies. Skeletal muscle fibers are truly fascinating in how responsive they are. With training, we can significantly improve muscle mass, strength and endurance. On the other hand, with age or extended ...

More cases of breast cancer detected with the help of AI

2023-09-09

One radiologist supported by AI detected more cases of breast cancer in screening mammography than two radiologists working together, reports the ScreenTrustCAD study from Karolinska Institutet in The Lancet Digital Health. The researchers say that AI is now ready to be implemented in breast cancer screening. For over 30 years, screening mammography has been an important key in reducing breast cancer mortality rates. However, challenges include a lack of radiologists and that not all cancers are detected. Several retrospective studies have shown that artificial ...

Mayo Clinic study reveals proton beam therapy may shorten breast cancer treatment

2023-09-09

ROCHESTER, Minn. — In a randomized trial, published in The Lancet Oncology, Mayo Clinic Comprehensive Cancer Center researchers uncover evidence supporting a shorter treatment time for breast cancer patients. The study compared two separate dosing schedules of pencil-beam scanning proton therapy, the most advanced type of proton therapy known for its precision in targeting cancer cells while preserving healthy tissue to reduce the risk of side effects. Survival rates for breast cancer continue to improve due to advances in diagnosis and treatment, leading to increasing emphasis on reducing the long-term ...

Study reveals human destruction of global floodplains

2023-09-09

A University of Texas at Arlington hydrologist’s study in the Nature journal Scientific Data provides the first-ever global estimate of human destruction of natural floodplains. The study can help guide future development in a way that can restore and conserve vital floodplain habitats that are critical to wildlife, water quality and reducing flood risk for people. Adnan Rajib, a UT Arlington assistant professor in the Department of Civil Engineering, was the lead author on the published study, “Human Alterations of the Global Floodplains.” His doctoral student, Qianjin Zheng, played a significant ...

Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: